AZD5305

• Research type

  Research Study

• Full title

  A Phase I, Open-label Study to Assess the Absolute Bioavailability of Saruparib (AZD5305) and Absorption, Distribution, Metabolism, and Excretion (ADME) of [14C]-Saruparib ([14C]-AZD5305) in Patients with Advanced Solid Malignancies

• IRAS ID

  1009645

• Contact name

  Adesola Obunge

• Contact email

  adesola.obunge@astrazeneca.com

• Sponsor organisation

  AstraZeneca AB

• Clinicaltrials.gov Identifier

  NCT06713369

• Research summary

  We are doing this study to learn more about the study drug, Saruparib, meaning how much your body absorbs and uses the given study drug, as well as how the study drug is processed and eliminated from your body (called pharmacokinetics). We will also investigate the safety of Saruparib in patients with advanced cancer, as well as gain a better understanding of the disease cancer and its associated health problems.

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  24/SC/0167

• Date of REC Opinion

  8 Aug 2024

• REC opinion

  Further Information Favourable Opinion